The rationale for combination therapy of rheumatoid arthritis based on pathophysiology

Journal of Rheumatology

Volumn 23, Issue SUPPL. 44, 1996, Pages 2-4

  Harris Jr , Edward D ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Combination therapy; Pathophysiology; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOSPORIN; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ARTICLE; DRUG COMBINATION; PATHOLOGY; SYNOVITIS; SYNOVIUM;

ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; SYNOVIAL MEMBRANE; SYNOVITIS;

EID: 0029959051     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (3)

1. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993;261 1727-30.
2. Harris ED Jr: Etiology and pathogenesis of rheumatoid arthritis. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds Textbook of Rheumatology. Philadelphia: WB Saunders, 1993.
3. Kavanaugh AF, Davis LS, Nichols LA, et al: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994;37:992-9.